Gilead Sciences (GILD) 89.33 $GILD
Pipeline Analysis and Sales Projections of the Top 25 Pharmaceutical Companies 2013-2023
M2 - 10 mins ago
Research and Markets (http://www.researchandmarkets.com/research/7pjm9m/top_25) has announced the addition of the "Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023" report to their offering. Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 takes a considered look at the pharmaceutical industry, including the late-term pipeline of major companies. This report provides long-term company sales forecasts which are based on 2013 market conditions. For each company, the report provides: - Revenues - R&D Spending 2007-2013 - Geographic Breakout of Revenues - Performance of Specific Products - Performance by Drug Category - Late-Stage Pipeline - Projections of Revenues to 2023 In addition to specific company data and factors, there are a number of macroeconomic concerns affecting sales such as aging populations, incidence of disease, unmet medical needs, government activities, and more. The pharmaceutical market as a whole has witnessed a number of significant changes in recent years, providing both setbacks and new opportunities. The number of blockbuster pharmaceuticals reaching patent and exclusivity expiration status and vulnerable to generic competition has changed the landscape of the market for many manufacturers. The growing interest in biotechnology development has transitioned an industry once focused on chemical-based therapies to biologic therapies and produced exceptional changes in many areas of medical treatment over the last two decades. The companies included in the study are: - Pfizer, inc. - Novartis AG - Roche ltd. - Merck & Co., inc. - Sanofi - Glaxosmithkline PLC - Johnson & johnson - Astra Zeneca plc - Eli Lilly and Company - Abbvie, inc. - Teva Pharmaceutical Industries, Ltd. - Amgen, inc. - Bristol-myers Squibb Company - Takeda Pharmaceutical co., LTD - Bayer AG - Novo nordisk - Boehringer Ingelheim gmbh - Daiichi Sankyo - Astellas - Gilead Sciences - Otsuka Pharmaceutical - Merck KGAA - Actavis - Mylan - Baxter international For more information visit http://www.researchandmarkets.com/research/7pjm9m/top_25
'Fast Money' Recap: Apple and Microsoft Earnings in the Spotlight
at The Street - 1 hr 10 mins ago
The trading panel discussed whether Apple's quarter was good enough, how PCs are benefiting Microsoft and whether it's time to start buying auto stocks.
Final Glance: Biotechnology companies
AP - Tue Jul 22, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
3 Things You Need to Watch on Gilead Sciences Inc. Earnings Call
Brian Orelli, The Motley Fool - Motley Fool - Tue Jul 22, 4:01PM CDT
Gilead Sciences plans to release second quarter financials on Wednesday. Here are three things investors should pay attention to during the conference call. 1. How sustainable are hepatitis C sales? This is literally the multi-billion dollar...
3 Quotes From Johnson & Johnson's Conference Call You Need to Read
Brian Orelli, The Motley Fool - Motley Fool - Tue Jul 22, 1:00PM CDT
Johnson & Johnson held a conference call last week to go over the results of its second-quarter financials and give investors a taste of what's to come. Here are three quotes from the call and some commentary about why they're so important. ...
Midday Glance: Biotechnology companies
AP - Tue Jul 22, 12:57PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Alexion, 3 Other Top Biotechs Reporting Earnings
at Investor's Business Daily - Tue Jul 22, 11:42AM CDT
The four highest-rated of the market's seven big-cap biotechs are set to report second-quarter earnings this week, each with its own unique storyline. Biogen Idec (BIIB), the subject of Tuesday's New America, will be first to report before the open...
Gilead Expected to Post Sky-High Hep C Sales in June Quarter
at The Street - Tue Jul 22, 11:12AM CDT
The buyside "whisper number" for Sovaldi sales is $3.5 billion. But everyone who follows Gilead knows this, which means the "whispered" whisper number for sales is $4 billion or more.
Do This Drug's Sales Make J&J a Hepatitis C Powerhouse?
Jeff Manera, The Motley Fool - Motley Fool - Tue Jul 22, 10:37AM CDT
Johnson & Johnson beat analyst second quarter earnings estimates last week, with an impressive quarterly net income increase of 13% and mostly optimistic projections going forward. So why, you may ask, did the shares tank by 2%? As so often...
Will Gilead (GILD) Earnings Disappoint in Q2 as Costs Rise? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 22, 10:20AM CDT
Gilead Sciences (GILD) is set to report second quarter 2014 results on Jul 23 after the market closes.
Early Glance: Biotechnology companies
AP - Tue Jul 22, 10:16AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
HIV pills show more promise to prevent infection
By The Associated Press - AP - Tue Jul 22, 9:37AM CDT
There is more good news about HIV treatment pills used to prevent infection in people at high risk of getting the AIDS virus: Follow-up from a landmark study that proved the drug works now shows that it does not encourage risky sex and is effective even if people skip some doses.
Gilead Earnings: Can Sovaldi Reach $3 Billion?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Mon Jul 21, 4:00PM CDT
Gilead Sciences reports earnings on July 23. According to Bloomberg, analysts are estimating over $2.8 billion in sales. But remember that analysts were off -- off by a lot! -- last quarter in guessing sales, with Gilead's $2.3 billion in Sovaldi...
Biogen Shares Rebound As Street Has A Change Of Heart
at Investor's Business Daily - Mon Jul 21, 3:09PM CDT
Biogen Idec heads into its second-quarter earnings report on one of its best rolls in years, as the biotech continues to benefit from heavy demand for its drugs to treat multiple sclerosis, cancer and autoimmune diseases. The No. 3 biotech by market...
Why I'm Shorting Gilead: Sentiment Is Too Positive Ahead of Earnings
at The Street - Mon Jul 21, 2:04PM CDT
Nobody thinks it's possible Gilead can sell off, bit it can. I dispel the hype and go short.
Yellen Hates Biotech Stocks! Should You?
Brian Orelli, The Motley Fool - Motley Fool - Mon Jul 21, 1:01PM CDT
Federal Reserve Chairwoman Janet Yellen thinks your small-cap biotech is overvalued. The Fed's Monetary Policy Report, released on July 15, had this to say: [V]aluation metrics in some sectors do appear substantially stretched -- particularly...
How Will Gilead Sciences (GILD) Stock Be Affected By Solvadi Hepatitis C Finding?
at The Street - Mon Jul 21, 7:22AM CDT
Shares of Gilead Sciences (GILD) are up in pre-market trade as the company's Solvadi drug helps cure hepatitis C in people with HIV, according to researchers.
Are Insurers Playing Fair With HIV Patients?
Todd Campbell, The Motley Fool - Motley Fool - Sun Jul 20, 1:00PM CDT
A new complaint claims that insurers may be flouting a key provision of the Affordable Care Act that prevents discrimination. As part of health-care insurance reform, this provision prevents insurers from denying coverage or pricing their plans based...
Roundtable: 3 Stocks Preparing to Shock the Market
Motley Fool Staff - Motley Fool - Sat Jul 19, 4:16PM CDT
Earnings season is upon us, so we decided to ask our top health care contributors to identify the stock they're watching to surprise on earnings. Here are the companies they singled out. George Budwell : Next week, I expect Cubist...
India Just Did What Millions of Americans Wish the U.S. Government Would Do
Sean Williams, The Motley Fool - Motley Fool - Sat Jul 19, 9:32AM CDT
The United States is unquestionably the premier economic superpower around the globe. It has the highest GDP, the greatest number of world-renowned universities, and of course has the most followed financial markets around the globe. Compared to...
Pipeline Analysis and Sales Projections of the Top 25 Pharmaceutical Companies 2013-2023
M2 - 10 mins ago
Research and Markets (http://www.researchandmarkets.com/research/7pjm9m/top_25) has announced the addition of the "Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023" report to their offering. Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 takes a considered look at the pharmaceutical industry, including the late-term pipeline of major companies. This report provides long-term company sales forecasts which are based on 2013 market conditions. For each company, the report provides: - Revenues - R&D Spending 2007-2013 - Geographic Breakout of Revenues - Performance of Specific Products - Performance by Drug Category - Late-Stage Pipeline - Projections of Revenues to 2023 In addition to specific company data and factors, there are a number of macroeconomic concerns affecting sales such as aging populations, incidence of disease, unmet medical needs, government activities, and more. The pharmaceutical market as a whole has witnessed a number of significant changes in recent years, providing both setbacks and new opportunities. The number of blockbuster pharmaceuticals reaching patent and exclusivity expiration status and vulnerable to generic competition has changed the landscape of the market for many manufacturers. The growing interest in biotechnology development has transitioned an industry once focused on chemical-based therapies to biologic therapies and produced exceptional changes in many areas of medical treatment over the last two decades. The companies included in the study are: - Pfizer, inc. - Novartis AG - Roche ltd. - Merck & Co., inc. - Sanofi - Glaxosmithkline PLC - Johnson & johnson - Astra Zeneca plc - Eli Lilly and Company - Abbvie, inc. - Teva Pharmaceutical Industries, Ltd. - Amgen, inc. - Bristol-myers Squibb Company - Takeda Pharmaceutical co., LTD - Bayer AG - Novo nordisk - Boehringer Ingelheim gmbh - Daiichi Sankyo - Astellas - Gilead Sciences - Otsuka Pharmaceutical - Merck KGAA - Actavis - Mylan - Baxter international For more information visit http://www.researchandmarkets.com/research/7pjm9m/top_25
'Fast Money' Recap: Apple and Microsoft Earnings in the Spotlight
at The Street - 1 hr 10 mins ago
The trading panel discussed whether Apple's quarter was good enough, how PCs are benefiting Microsoft and whether it's time to start buying auto stocks.
Final Glance: Biotechnology companies
AP - Tue Jul 22, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
3 Things You Need to Watch on Gilead Sciences Inc. Earnings Call
Brian Orelli, The Motley Fool - Motley Fool - Tue Jul 22, 4:01PM CDT
Gilead Sciences plans to release second quarter financials on Wednesday. Here are three things investors should pay attention to during the conference call. 1. How sustainable are hepatitis C sales? This is literally the multi-billion dollar...
3 Quotes From Johnson & Johnson's Conference Call You Need to Read
Brian Orelli, The Motley Fool - Motley Fool - Tue Jul 22, 1:00PM CDT
Johnson & Johnson held a conference call last week to go over the results of its second-quarter financials and give investors a taste of what's to come. Here are three quotes from the call and some commentary about why they're so important. ...
Midday Glance: Biotechnology companies
AP - Tue Jul 22, 12:57PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Alexion, 3 Other Top Biotechs Reporting Earnings
at Investor's Business Daily - Tue Jul 22, 11:42AM CDT
The four highest-rated of the market's seven big-cap biotechs are set to report second-quarter earnings this week, each with its own unique storyline. Biogen Idec (BIIB), the subject of Tuesday's New America, will be first to report before the open...
Gilead Expected to Post Sky-High Hep C Sales in June Quarter
at The Street - Tue Jul 22, 11:12AM CDT
The buyside "whisper number" for Sovaldi sales is $3.5 billion. But everyone who follows Gilead knows this, which means the "whispered" whisper number for sales is $4 billion or more.
Do This Drug's Sales Make J&J a Hepatitis C Powerhouse?
Jeff Manera, The Motley Fool - Motley Fool - Tue Jul 22, 10:37AM CDT
Johnson & Johnson beat analyst second quarter earnings estimates last week, with an impressive quarterly net income increase of 13% and mostly optimistic projections going forward. So why, you may ask, did the shares tank by 2%? As so often...
Will Gilead (GILD) Earnings Disappoint in Q2 as Costs Rise? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 22, 10:20AM CDT
Gilead Sciences (GILD) is set to report second quarter 2014 results on Jul 23 after the market closes.
Early Glance: Biotechnology companies
AP - Tue Jul 22, 10:16AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
HIV pills show more promise to prevent infection
By The Associated Press - AP - Tue Jul 22, 9:37AM CDT
There is more good news about HIV treatment pills used to prevent infection in people at high risk of getting the AIDS virus: Follow-up from a landmark study that proved the drug works now shows that it does not encourage risky sex and is effective even if people skip some doses.
Gilead Earnings: Can Sovaldi Reach $3 Billion?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Mon Jul 21, 4:00PM CDT
Gilead Sciences reports earnings on July 23. According to Bloomberg, analysts are estimating over $2.8 billion in sales. But remember that analysts were off -- off by a lot! -- last quarter in guessing sales, with Gilead's $2.3 billion in Sovaldi...
Biogen Shares Rebound As Street Has A Change Of Heart
at Investor's Business Daily - Mon Jul 21, 3:09PM CDT
Biogen Idec heads into its second-quarter earnings report on one of its best rolls in years, as the biotech continues to benefit from heavy demand for its drugs to treat multiple sclerosis, cancer and autoimmune diseases. The No. 3 biotech by market...
Why I'm Shorting Gilead: Sentiment Is Too Positive Ahead of Earnings
at The Street - Mon Jul 21, 2:04PM CDT
Nobody thinks it's possible Gilead can sell off, bit it can. I dispel the hype and go short.
Yellen Hates Biotech Stocks! Should You?
Brian Orelli, The Motley Fool - Motley Fool - Mon Jul 21, 1:01PM CDT
Federal Reserve Chairwoman Janet Yellen thinks your small-cap biotech is overvalued. The Fed's Monetary Policy Report, released on July 15, had this to say: [V]aluation metrics in some sectors do appear substantially stretched -- particularly...
How Will Gilead Sciences (GILD) Stock Be Affected By Solvadi Hepatitis C Finding?
at The Street - Mon Jul 21, 7:22AM CDT
Shares of Gilead Sciences (GILD) are up in pre-market trade as the company's Solvadi drug helps cure hepatitis C in people with HIV, according to researchers.
Are Insurers Playing Fair With HIV Patients?
Todd Campbell, The Motley Fool - Motley Fool - Sun Jul 20, 1:00PM CDT
A new complaint claims that insurers may be flouting a key provision of the Affordable Care Act that prevents discrimination. As part of health-care insurance reform, this provision prevents insurers from denying coverage or pricing their plans based...
Roundtable: 3 Stocks Preparing to Shock the Market
Motley Fool Staff - Motley Fool - Sat Jul 19, 4:16PM CDT
Earnings season is upon us, so we decided to ask our top health care contributors to identify the stock they're watching to surprise on earnings. Here are the companies they singled out. George Budwell : Next week, I expect Cubist...
India Just Did What Millions of Americans Wish the U.S. Government Would Do
Sean Williams, The Motley Fool - Motley Fool - Sat Jul 19, 9:32AM CDT
The United States is unquestionably the premier economic superpower around the globe. It has the highest GDP, the greatest number of world-renowned universities, and of course has the most followed financial markets around the globe. Compared to...
